Is NVCT or AMLX more profitable?

Amylyx Pharmaceuticals' return on equity of -52.92% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -184.25% -105.24% Amylyx Pharmaceuticals N/A -52.92% -48.53%

Does the media favor NVCT or AMLX?

In the previous week, Nuvectis Pharma had 2 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 18 mentions for Nuvectis Pharma and 16 mentions for Amylyx Pharmaceuticals. Nuvectis Pharma's average media sentiment score of 0.30 beat Amylyx Pharmaceuticals' score of 0.08 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Amylyx Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to NVCT or BCRX?

In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Nuvectis Pharma. MarketBeat recorded 20 mentions for BioCryst Pharmaceuticals and 18 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.30 beat BioCryst Pharmaceuticals' score of 0.23 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral BioCryst Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, NVCT or SION?

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A Sionna Therapeutics N/A N/A -$75.27M -$2.18 N/A

Is NVCT or SION more profitable?

Sionna Therapeutics' return on equity of -32.94% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -184.25% -105.24% Sionna Therapeutics N/A -32.94% -31.08%

Does the media refer more to NVCT or SION?

In the previous week, Sionna Therapeutics had 2 more articles in the media than Nuvectis Pharma. MarketBeat recorded 20 mentions for Sionna Therapeutics and 18 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.30 beat Sionna Therapeutics' score of -0.18 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Sionna Therapeutics 1 Very Positive mention(s) 7 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, SLS or NVCT?

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SELLAS Life Sciences Group N/A N/A -$26.86M -$0.23 N/A Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A

Is SLS or NVCT more profitable?

SELLAS Life Sciences Group's return on equity of -47.12% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences Group N/A -47.12% -42.63% Nuvectis Pharma N/A -184.25% -105.24%

Does the media prefer SLS or NVCT?

In the previous week, Nuvectis Pharma had 16 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 18 mentions for Nuvectis Pharma and 2 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.65 beat Nuvectis Pharma's score of 0.30 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvectis Pharma 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to NVCT or NUVB?

In the previous week, Nuvectis Pharma had 6 more articles in the media than Nuvation Bio. MarketBeat recorded 18 mentions for Nuvectis Pharma and 12 mentions for Nuvation Bio. Nuvectis Pharma's average media sentiment score of 0.30 beat Nuvation Bio's score of 0.19 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Nuvation Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Nuvectis Pharma (NVCT) Competitors

$18.86 -0.09 (-0.47%)

As of 03:04 PM Eastern

Compare

NVCT vs. AMLX, BCRX, SION, SLS, and NUVB

Should you buy Nuvectis Pharma stock or one of its competitors? MarketBeat compares Nuvectis Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvectis Pharma include Amylyx Pharmaceuticals (AMLX), BioCryst Pharmaceuticals (BCRX), Sionna Therapeutics (SION), SELLAS Life Sciences Group (SLS), and Nuvation Bio (NUVB). These companies are all part of the "biotechnology" industry.

How does Nuvectis Pharma compare to Amylyx Pharmaceuticals?

Nuvectis Pharma (NASDAQ:NVCT) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

In the previous week, Nuvectis Pharma had 2 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 18 mentions for Nuvectis Pharma and 16 mentions for Amylyx Pharmaceuticals. Nuvectis Pharma's average media sentiment score of 0.30 beat Amylyx Pharmaceuticals' score of 0.08 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Amylyx Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvectis Pharma has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Amylyx Pharmaceuticals	$87.37M	28.67	-$144.74M	-$1.43	N/A

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 28.6% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Amylyx Pharmaceuticals' return on equity of -52.92% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

Nuvectis Pharma has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.21, suggesting that its share price is 121% less volatile than the broader market.

Nuvectis Pharma presently has a consensus price target of $35.00, indicating a potential upside of 85.58%. Amylyx Pharmaceuticals has a consensus price target of $25.38, indicating a potential upside of 12.88%. Given Nuvectis Pharma's higher possible upside, research analysts clearly believe Nuvectis Pharma is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Summary

Nuvectis Pharma beats Amylyx Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Nuvectis Pharma compare to BioCryst Pharmaceuticals?

Nuvectis Pharma (NASDAQ:NVCT) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Nuvectis Pharma has a beta of -0.26, indicating that its share price is 126% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Nuvectis Pharma presently has a consensus price target of $35.00, suggesting a potential upside of 85.58%. BioCryst Pharmaceuticals has a consensus price target of $20.60, suggesting a potential upside of 113.36%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

BioCryst Pharmaceuticals has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
BioCryst Pharmaceuticals	$874.84M	2.82	$263.86M	-$1.50	N/A

Nuvectis Pharma has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. BioCryst Pharmaceuticals' return on equity of -86.89% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 28.6% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Nuvectis Pharma. MarketBeat recorded 20 mentions for BioCryst Pharmaceuticals and 18 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.30 beat BioCryst Pharmaceuticals' score of 0.23 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
BioCryst Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BioCryst Pharmaceuticals beats Nuvectis Pharma on 10 of the 15 factors compared between the two stocks.

How does Nuvectis Pharma compare to Sionna Therapeutics?

Nuvectis Pharma (NASDAQ:NVCT) and Sionna Therapeutics (NASDAQ:SION) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Sionna Therapeutics' return on equity of -32.94% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
Sionna Therapeutics	N/A	-32.94%	-31.08%

In the previous week, Sionna Therapeutics had 2 more articles in the media than Nuvectis Pharma. MarketBeat recorded 20 mentions for Sionna Therapeutics and 18 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.30 beat Sionna Therapeutics' score of -0.18 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sionna Therapeutics	1 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvectis Pharma currently has a consensus price target of $35.00, suggesting a potential upside of 85.58%. Sionna Therapeutics has a consensus price target of $42.22, suggesting a potential upside of 852.02%. Given Sionna Therapeutics' higher possible upside, analysts plainly believe Sionna Therapeutics is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Sionna Therapeutics	1 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.31

96.8% of Nuvectis Pharma shares are owned by institutional investors. 28.6% of Nuvectis Pharma shares are owned by insiders. Comparatively, 5.1% of Sionna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A

Nuvectis Pharma has a beta of -0.26, meaning that its share price is 126% less volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market.

Summary

Sionna Therapeutics beats Nuvectis Pharma on 8 of the 14 factors compared between the two stocks.

How does Nuvectis Pharma compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Nuvectis Pharma (NASDAQ:NVCT) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Comparatively, 28.6% of Nuvectis Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

In the previous week, Nuvectis Pharma had 16 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 18 mentions for Nuvectis Pharma and 2 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.65 beat Nuvectis Pharma's score of 0.30 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvectis Pharma	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

SELLAS Life Sciences Group's return on equity of -47.12% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%
Nuvectis Pharma	N/A	-184.25%	-105.24%

SELLAS Life Sciences Group presently has a consensus target price of $10.00, suggesting a potential downside of 10.67%. Nuvectis Pharma has a consensus target price of $35.00, suggesting a potential upside of 85.58%. Given Nuvectis Pharma's higher possible upside, analysts plainly believe Nuvectis Pharma is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

SELLAS Life Sciences Group has a beta of 2.48, indicating that its stock price is 148% more volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market.

Summary

Nuvectis Pharma beats SELLAS Life Sciences Group on 6 of the 11 factors compared between the two stocks.

How does Nuvectis Pharma compare to Nuvation Bio?

Nuvectis Pharma (NASDAQ:NVCT) and Nuvation Bio (NYSE:NUVB) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 28.6% of Nuvectis Pharma shares are held by company insiders. Comparatively, 30.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Nuvectis Pharma has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Nuvation Bio	$62.90M	36.18	-$204.63M	-$0.44	N/A

Nuvectis Pharma currently has a consensus price target of $35.00, indicating a potential upside of 85.58%. Nuvation Bio has a consensus price target of $13.00, indicating a potential upside of 98.93%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts plainly believe Nuvation Bio is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Nuvectis Pharma has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Nuvation Bio's return on equity of -46.59% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
Nuvation Bio	-88.18%	-46.59%	-22.01%

Nuvectis Pharma has a beta of -0.26, meaning that its stock price is 126% less volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

In the previous week, Nuvectis Pharma had 6 more articles in the media than Nuvation Bio. MarketBeat recorded 18 mentions for Nuvectis Pharma and 12 mentions for Nuvation Bio. Nuvectis Pharma's average media sentiment score of 0.30 beat Nuvation Bio's score of 0.19 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Nuvation Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Nuvation Bio beats Nuvectis Pharma on 9 of the 15 factors compared between the two stocks.

Get Nuvectis Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVCT vs. The Competition

Export

Metric	Nuvectis Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$614.30M	$3.71B	$7.04B	$12.94B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-14.39	9.08	269.98	24.78
Price / Sales	N/A	1,268.95	651.07	108.19
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	26.19	17.65	11.26	6.43
Net Income	-$26.44M	-$13.25M	$3.45B	$347.27M
7 Day Performance	-12.69%	5.21%	3.50%	2.54%
1 Month Performance	2.78%	-1.91%	-0.64%	-1.00%
1 Year Performance	214.33%	60.70%	77.23%	23.33%

Nuvectis Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVCT Nuvectis Pharma	3.9382 of 5 stars	$18.86 -0.5%	$35.00 +85.6%	+215.8%	$614.30M	N/A	N/A	8	Earnings Report
AMLX Amylyx Pharmaceuticals	2.9581 of 5 stars	$21.81 +8.1%	$25.38 +16.3%	+198.7%	$2.24B	$87.37M	N/A	200	Earnings Report Analyst Revision
BCRX BioCryst Pharmaceuticals	3.2297 of 5 stars	$9.02 +2.4%	$20.80 +130.6%	+13.0%	$2.24B	$874.84M	N/A	530	Earnings Report Analyst Upgrade
SION Sionna Therapeutics	2.9535 of 5 stars	$49.94 +1.4%	$53.22 +6.6%	+188.9%	$2.22B	N/A	N/A	35	Trending News Earnings Report Analyst Forecast Gap Down
SLS SELLAS Life Sciences Group	0.9956 of 5 stars	$11.81 +5.3%	$10.00 -15.3%	+660.1%	$2.21B	N/A	N/A	10	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVCT) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvectis Pharma (NVCT) Competitors

NVCT vs. AMLX, BCRX, SION, SLS, and NUVB

How does Nuvectis Pharma compare to Amylyx Pharmaceuticals?

Summary

How does Nuvectis Pharma compare to BioCryst Pharmaceuticals?

Summary

How does Nuvectis Pharma compare to Sionna Therapeutics?

Summary

How does Nuvectis Pharma compare to SELLAS Life Sciences Group?

Summary

How does Nuvectis Pharma compare to Nuvation Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT vs. The Competition

Nuvectis Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvectis Pharma (NVCT) Competitors

NVCT vs. AMLX, BCRX, SION, SLS, and NUVB

How does Nuvectis Pharma compare to Amylyx Pharmaceuticals?

Does the media favor NVCT or AMLX?

Which has stronger earnings & valuation, NVCT or AMLX?

Do insiders and institutionals believe in NVCT or AMLX?

Is NVCT or AMLX more profitable?

Which has more risk and volatility, NVCT or AMLX?

Do analysts recommend NVCT or AMLX?

Summary

How does Nuvectis Pharma compare to BioCryst Pharmaceuticals?

Which has more risk & volatility, NVCT or BCRX?

Do analysts prefer NVCT or BCRX?

Which has better valuation & earnings, NVCT or BCRX?

Is NVCT or BCRX more profitable?

Do insiders & institutionals hold more shares of NVCT or BCRX?

Does the media refer more to NVCT or BCRX?

Summary

How does Nuvectis Pharma compare to Sionna Therapeutics?

Is NVCT or SION more profitable?

Does the media refer more to NVCT or SION?

Do analysts rate NVCT or SION?

Do insiders and institutionals hold more shares of NVCT or SION?

Which has higher earnings & valuation, NVCT or SION?

Which has more volatility & risk, NVCT or SION?

Summary

How does Nuvectis Pharma compare to SELLAS Life Sciences Group?

Do insiders & institutionals hold more shares of SLS or NVCT?

Which has stronger valuation and earnings, SLS or NVCT?

Does the media prefer SLS or NVCT?

Is SLS or NVCT more profitable?

Do analysts recommend SLS or NVCT?

Which has more volatility & risk, SLS or NVCT?

Summary

How does Nuvectis Pharma compare to Nuvation Bio?

Do institutionals and insiders have more ownership in NVCT or NUVB?

Which has better earnings & valuation, NVCT or NUVB?

Do analysts recommend NVCT or NUVB?

Is NVCT or NUVB more profitable?

Which has more volatility and risk, NVCT or NUVB?

Does the media refer more to NVCT or NUVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT vs. The Competition

Nuvectis Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools